Twin Capital Management Inc. Decreases Position in Johnson & Johnson (NYSE:JNJ)

Twin Capital Management Inc. cut its stake in Johnson & Johnson (NYSE:JNJ) by 2.1% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 57,826 shares of the company’s stock after selling 1,228 shares during the quarter. Johnson & Johnson comprises approximately 1.2% of Twin Capital Management Inc.’s portfolio, making the stock its 13th biggest holding. Twin Capital Management Inc.’s holdings in Johnson & Johnson were worth $9,064,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Bond & Devick Financial Network Inc. lifted its stake in Johnson & Johnson by 6.4% in the 3rd quarter. Bond & Devick Financial Network Inc. now owns 6,531 shares of the company’s stock valued at $1,017,000 after buying an additional 393 shares in the last quarter. Worth Financial Advisory Group LLC lifted its stake in Johnson & Johnson by 4.9% in the 3rd quarter. Worth Financial Advisory Group LLC now owns 11,537 shares of the company’s stock worth $1,797,000 after purchasing an additional 542 shares in the last quarter. Ritholtz Wealth Management lifted its stake in Johnson & Johnson by 90.9% in the 3rd quarter. Ritholtz Wealth Management now owns 41,394 shares of the company’s stock worth $6,447,000 after purchasing an additional 19,714 shares in the last quarter. Arkadios Wealth Advisors lifted its stake in Johnson & Johnson by 54.3% in the 3rd quarter. Arkadios Wealth Advisors now owns 71,925 shares of the company’s stock worth $11,202,000 after purchasing an additional 25,298 shares in the last quarter. Finally, Venture Visionary Partners LLC lifted its stake in Johnson & Johnson by 0.4% in the 3rd quarter. Venture Visionary Partners LLC now owns 99,877 shares of the company’s stock worth $15,558,000 after purchasing an additional 373 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 0.3 %

Johnson & Johnson stock opened at $149.56 on Wednesday. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16. The firm has a 50 day moving average price of $155.83 and a 200 day moving average price of $155.51. The company has a market capitalization of $360.41 billion, a PE ratio of 9.32, a price-to-earnings-growth ratio of 2.44 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.43%. The firm had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. During the same quarter last year, the firm earned $2.68 EPS. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. Research analysts expect that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.32%. The ex-dividend date of this dividend is Monday, May 20th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Analyst Ratings Changes

JNJ has been the topic of a number of research reports. Royal Bank of Canada decreased their target price on shares of Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 17th. Bank of America decreased their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their target price for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. Raymond James raised their target price on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $175.86.

Insiders Place Their Bets

In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares in the company, valued at $105,810,030.75. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares in the company, valued at $22,099,078.32. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.